Figure 1.

Trimodality therapy in HT1080 xenografts. (A) Growth of HT1080 fibrosarcoma xenografts in athymic nude mice. Groups were treated with control IgG 20 mg kg⁻¹ three times per week, DC101 20 mg kg⁻¹ three times per week, RT 8 Gy one time, and/or TH-302 50 mg kg⁻¹ five times per week. Graphs and photos of microvessel density (B), endothelial cell (EC)-specific apoptosis (C), nuclear HIF-1α expression (D), and cytoplasmic CA-9 expression (E) in HT1080 tumours groups. Scale bars, 20 μm. Bars represent s.d. P<0.05 compared to control group. **P<0.05 compared with all other groups.